Cervical cancer causes over 300,000 deaths per year. The introduction of screening programs to detect pre-cancer lesions has resulted in a 50 percent reduction of premature deaths. However, non-attendance rates are high: on average 40 percent of women living in developed countries and 80 percent in developing countries do not participate in screening due to the invasiveness of cervical sampling, cultural reasons, lack of time, and the need to visit a clinician.
This whitepaper from Novosanis explains the performance of Colli-Pee — a self-sampling urine-capturing device that collects the first 20 ml of urine flow — in HPV-based cervical cancer screening, highlighting current studies and literature in the field and demonstrating the device’s use for non-invasive, self-administered screening.
Offered Free by: Novosanis NV
See All Resources from: Novosanis NV